Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Nature Communications

Volumn 6, Issue , 2015, Pages

  Witkiewicz, Agnieszka K ^a,b   McMillan, Elizabeth A ^c   Balaji, Uthra ^b   Baek, GuemHee ^b   Lin, Wan Chi ^d   Mansour, John ^c   Mollaee, Mehri ^e   Wagner, Kay Uwe ^d   Koduru, Prasad ^b   Yopp, Adam ^c   Choti, Michael A ^c   Yeo, Charles J ^e   McCue, Peter ^e   White, Michael A ^a,c   Knudsen, Erik S ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CHROMOSOME; DIGESTIVE SYSTEM DISORDER; DISEASE TREATMENT; DNA; ETIOLOGY; GENETIC VARIATION; MUTATION; TUMOR;

ADULT; AGED; ALLELE; ARTICLE; CELL CYCLE; CODON; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA REPAIR; ENVIRONMENTAL STRESS; EXOME; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HEDGEHOG; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICRODISSECTION; MULTIPLE CANCER; PANCREAS ADENOCARCINOMA; SIGNAL TRANSDUCTION; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, PANCREATIC DUCTAL; DNA SEQUENCE; DRUG RESISTANCE; GENE AMPLIFICATION; GENETIC VARIATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; ONCOGENE MYC; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; VERY ELDERLY; WNT SIGNALING PATHWAY;

ERINACEIDAE;

ANTINEOPLASTIC AGENT; ARID1A PROTEIN, HUMAN; B RAF KINASE; BRAF PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; INDOLE DERIVATIVE; KRAS PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN P21; PROTEIN P53; RBM10 PROTEIN, HUMAN; RETINOBLASTOMA PROTEIN; RNA BINDING PROTEIN; SULFONAMIDE; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; VEMURAFENIB;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRCA2 PROTEIN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, PANCREATIC DUCTAL; CELL CYCLE; DNA COPY NUMBER VARIATIONS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; EXOME; FEMALE; GENE AMPLIFICATION; GENES, MYC; GENETIC VARIATION; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RETINOBLASTOMA PROTEIN; RNA-BINDING PROTEINS; SEQUENCE ANALYSIS, DNA; SULFONAMIDES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; WNT SIGNALING PATHWAY;

EID: 84927144113     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7744     Document Type: Article

References (42)

1. Paulson, A. S., Tran Cao, H. S., Tempero, M. A. & Lowy, A. M. Therapeutic advances in pancreatic cancer. Gastroenterology 144, 1316-1326 (2013).
2. Cowan, R. W. & Maitra, A. Genetic progression of pancreatic cancer. Cancer J. 20, 80-84 (2014).
3. Vincent, A., Herman, J., Schulick, R., Hruban, R. H. & Goggins, M. Pancreatic cancer. Lancet 378, 607-620 (2011).
4. Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399-405 (2012).
5. Jones, S. et al. Core signalling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
6. Erkan, M., Reiser-Erkan, C., Michalski, C. W. & Kleeff, J. Tumour microenvironment and progression of pancreatic cancer. Exp. Oncol. 32, 128-131 (2010).
7. Cancer Genome Atlas Research, N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
8. Yeo, C. J. et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann. Surg. 226, 248-257 (1997).
9. Weber, C. E. et al. Clinical and pathologic features influencing survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. J. Gastrointest. Surg. 18, 340-347 (2014).
10. Barbieri, C. E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
11. Cancer Genome Atlas Research Network et al. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
12. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
13. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15, 585-598 (2014).
14. Henderson, S., Chakravarthy, A., Su, X., Boshoff, C. & Fenton, T. R. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumour development. Cell Rep. 7, 1833-1841 (2014).
15. Lin, W. C. et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 73, 1821-1830 (2013).
16. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
17. Furukawa, T. et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci. Rep. 1, 161 (2011).
18. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
19. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
20. Inoue, A. et al. RBM10 regulates alternative splicing. FEBS Lett. 588, 942-947 (2014).
21. Helming, K. C. et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20, 251-254 (2014).
22. Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signalling and clinical outcome. J. Natl. Cancer Inst. 104, 228-239 (2012).
23. Collisson, E. A. et al. A central role for RAF-->MEK-->ERK signalling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov. 2, 685-693 (2012).
24. Jiang, X. et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proc. Natl Acad. Sci. USA 110, 12649-12654 (2013).
25. Franco, J., Witkiewicz, A. K. & Knudsen, E. S. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget 5, 6512-6525 (2014).
26. van der Heijden, M. S. et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumour. Clin. Cancer Res. 11, 7508-7515 (2005).
27. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
28. Yadav, D. & Lowenfels, A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144, 1252-1261 (2013).
29. Klein, A. P., Hruban, R. H., Brune, K. A., Petersen, G. M. & Goggins, M. Familial pancreatic cancer. Cancer J. 7, 266-273 (2001).
30. Jones, S. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324, 217 (2009).
31. Holzmann, K. et al. Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res. 64, 4428-4433 (2004).
32. Liu, C. et al. The UPF1 R. N. A. surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat. Med. 20, 596-598 (2014).
33. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
34. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
35. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568-576 (2012).
36. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
37. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
38. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).
39. Shi, T., Seligson, D., Belldegrun, A. S., Palotie, A. & Horvath, S. Tumour classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod. Pathol. 18, 547-557 (2005).
40. Frey, B. J. & Dueck, D. Clustering by passing messages between data points. Science 315, 972-976 (2007).
41. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
42. Goode, D. L. et al. A simple consensus approach improves somatic mutation prediction accuracy. Genome Med. 5, 90 (2013).